Metrics to compare | CU6 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCU6PeersSector | |
|---|---|---|---|---|
P/E Ratio | −6.2x | −3.8x | −0.2x | |
PEG Ratio | 0.14 | −0.05 | 0.00 | |
Price/Book | 3.5x | 2.5x | 2.6x | |
Price / LTM Sales | 62.7x | 4.9x | 2.7x | |
Upside (Analyst Target) | 299.8% | 264.1% | 72.2% | |
Fair Value Upside | Unlock | 17.4% | 12.4% | Unlock |
Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, engages in research and development of radiopharmaceutical products for oncology in Australia and the United States. The company’s lead product is SAR-bisPSMA, a theranostic radiopharmaceutical for the treatment of Prostate Specific Membrane Antigen (PSMA) cancer. It also develops SAR-Bombesin, a pan cancer theranostic radiopharmaceutical to treat prostate, breast, ovarian, urinary, small cell lung cancer, as well as glioblastoma and gastrointestinal stromal tumours; and SARTATE, a theranostic radiopharmaceutical for the treatment of somatostatin receptor 2 (SSTR2) cancer. Clarity Pharmaceuticals Ltd was incorporated in 2010 and is based in Sydney, Australia.